| Literature DB >> 28778680 |
Martha Kirstine Haahr1, Nessn H Azawi2, Line Grønbaek Andersen3, Steen Carlson4, Lars Lund5.
Abstract
INTRODUCTION: Radical prostatectomy (RP) offers a good long-term cancer control for clinically localized prostate cancer. However, complications such as erectile dysfunction and substantial decreases quality of life of the afflicted men and their sexual partners. Identification of pre-, per-, and postoperative factors that correlate with poor postoperative erectile status must be considered an important step to improving penile rehabilitation. AIM: To describe postoperative erectile function after RP in a Danish cohort.Entities:
Keywords: Erectile Aids; Erectile Dysfunction; Penile Rehabilitation; Prostate Cancer; Radical Prostatectomy
Year: 2017 PMID: 28778680 PMCID: PMC5562492 DOI: 10.1016/j.esxm.2017.06.003
Source DB: PubMed Journal: Sex Med ISSN: 2050-1161 Impact factor: 2.491
Figure 1Flowchart showing the inclusion process. RP = radical prostatectomy.
Demographics and clinical data of the cohort∗
| Characteristics | Total | Erectile dysfunction | Erectile function sufficient for intercourse | |
|---|---|---|---|---|
| Subjects | 704 | 478 (67.9) | 226 (32.1) | |
| Patient age (y) | 62 ± 5.8 | 63.2 ± 5.5 | 60 ± 5.9 | <.01 |
| Age < 63 y | 387 | 230 | 157 | <.0001 |
| Age > 63 y | 317 | 248 | 69 | |
| Body mass index (kg/m2) | 26.7 ± 3.2 | 26.7 ± 3.2 | 27.0 ± 3.2 | <.02 |
| Not stated | 293 (41.6) | 189 (39.5) | 104 (46) | |
| Normal > 19 | 127 (30.9) | 99 (34.3) | 28 (23) | |
| Overweight > 25 | 220 (53.5) | 146 (50.5) | 74 (60.7) | |
| Obese > 30 | 64 (15.6) | 44 (15.2) | 20 (16.4) | |
| Smoker | 119 (19.3) | 77 (18) | 42 (22.1) | .27 |
| Alcohol overuse | 105 (18.7) | 70 (18) | 35 (20.4) | .07 |
| Diabetes | 27 (3.8) | 22 (4.6) | 5 (2.2) | .15 |
| Hypercholesterolemia | 161 (22.9) | 115 (24.1) | 46 (20.4) | .28 |
| Hypertension | 274 (38.9) | 208 (43.5) | 66 (29.2) | <.05 |
| ASA PS 1 | 273 (40.1) | 166 | 107 (48.9) | <.01 |
| ASA PS 2 | 387 (56.9) | 278 | 109 (49.8) | |
| ASA PS 3 | 20 (2.9) | 17 | 3 (1.4) | |
| ASA PS not stated | 24 (3.5) | 17 (3.6) | 7 (3.1) |
ASA PS = American Society of Anesthesiologists Physical Status.
Data are presented as mean ± SD or number (percentage).
Surgical and pathologic characteristics of cohort∗
| Characteristics | Total | Erectile dysfunction | Erectile function sufficient for intercourse | |
|---|---|---|---|---|
| Subjects | 704 | 478 (67.9) | 226 (32.1) | |
| Preoperative PSA (ng/mL) | 10.0 ± 5.6 | 10.6 ± 8.1 | 9.8 ± 6.2 | .13 |
| Surgical approach | ||||
| Open | 524 (74.4) | 353 (73.8) | 171 (75.7) | |
| RALP | 180 (25.6) | 125 (26.2) | 55 (24.3) | .64 |
| Nerve-sparing status | ||||
| None | 445 (63.2) | 346 (72.4) | 134 (59.3) | |
| Unilateral | 74 (10.5) | 35 (7.3) | 27 (11.9) | <.04 |
| Bilateral | 185 (26.3) | 97 (20.3) | 65 (28.8) | |
| Pathologic tumor stage | ||||
| T1–T2a | 48 (6.8) | 25 (5.24) | 23 (10.2) | |
| T2b | 17 (2.4) | 11 (2.3) | 6 (2.7) | .17 |
| T2c | 552 (78.4) | 379 (79.3) | 173 (76.5) | |
| pT3a + b | 60 (8.5) | 44 (9.2) | 16 (7.1) | |
| T3b | 27 (3.8) | 19 (4) | 8 (3.5) | |
| Gleason score | ||||
| ≤6 | 121 (17.1) | 68 (14.3) | 53 (23.5) | <.02 |
| 3 + 4 | 392 (55.7) | 270 (56.5) | 122 (54) | |
| 4 + 3 | 148 (21.1) | 111 (23.4) | 37 (16.4) | |
| 8 | 28 (4) | 18 (3.8) | 10 (4.4) | |
| ≥9 | 15 (2.2) | 11 (2.3) | 4 (1.8) | |
| Positive surgical margins | 109 (15.5) | 76 (10.8) | 33 (14.6) | .56 |
PSA = prostate-specific antigen; RALP = robot-assisted laparoscopic prostatectomy.
Data are presented as mean ± SD or number (percentage).
Results of erectile function 12 months after radical prostatectomy
| ED | 478 (67.9%) |
| 1. Lack of interest in penile rehabilitation | 155 (22%) |
| 2. Did not resume sex life | 26 (3.7%) |
| 3. No further elaborated ED | 56 (8.0%) |
| 4. Sexually active but could not achieve ESI | 241 (34.2%) |
| Using PDE-5i | 30 (12.5%) |
| Using injection therapy | 6 (2.5%) |
| Tried PDE-5i | 91 (37.8%) |
| Tried injection therapy | 4 (1.7%) |
| Referred for further sexual rehabilitation | 117 (48.5%) |
| ESI | 226 (32.1%) |
| PDE-5i | 90 (39.8%) |
| Injection therapy | 18 (8.4%) |
| Using vacuum erect device | 1 (0.4%) |
| Not stated | 40 (17.7%) |
ED = erectile dysfunction; ESI = self-reported erection sufficient for intercourse; injection therapy = intracavernous injections of alprostadil; PDE-5i = phosphodiesterase type 5 inhibitor.
Some patients might be in more than one group. No patient had been using intraurethral agents and none had been offered penile prosthesis placement.